Piper Sandler Maintains Neutral on Caris Life Sciences, Raises Price Target to $25
Benzinga Newsdesk 5 hours ago
Analyst RatingsNewsPrice Target
Piper Sandler analyst David Westenberg maintains Caris Life Sciences (NASDAQ:CAI) with a Neutral and raises the price target from $22 to $25.
Piper Sandler analyst David Westenberg maintains Caris Life Sciences (NASDAQ:CAI) with a Neutral and raises the price target from $22 to $25.